Naxitamab

(Danyelza®)

Danyelza®

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 40 mg/10 mL (4 mg/mL))
Drug ClassGD2-binding monoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Danyelza (naxitamab-gqgk) Prescribing Information.2020Y-mAbs Therapeutics, Inc., New York, NY

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
Data not availableSubjects
F: undefined%
M: undefined%
2020Journal of Clinical Oncology